Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Steven Pavletic, M.D., National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00076752
First received: February 2, 2004
Last updated: June 13, 2014
Last verified: June 2014
Results First Received: March 25, 2014  
Study Type: Interventional
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: fludarabine phosphate
Drug: cyclophosphamide
Biological: Rituxan (rituximab)
Biological: filgrastim
Drug: methylprednisolone
Other: immunologic technique
Other: laboratory biomarker analysis
Procedure: autologous hematopoietic stem cell transplantation
Drug: Diphenhydramine
Drug: Mesna

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Autologous HSCT in SLE

Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).

SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, and diphenhydramine. Stem cell transplant infusion day 0, product will be infused rapidly intravenously after premedication with diphenhydramine 25-60 mg orally or intravenous.


Participant Flow:   Overall Study
    Autologous HSCT in SLE  
STARTED     9  
COMPLETED     6  
NOT COMPLETED     3  
Death                 2  
Withdrawal per PI, PI put study on hold                 1  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Autologous HSCT in SLE

Autologous hematopoietic stem cell transplantation (HSCT) in systemic lupus erythematosus (SLE).

SLE is a chronic, inflammatory disease of the immune system. Participants received a priming, conditioning and transplant regimen. Priming regimen consisted of treatment with rituxan, filgrastim, cyclophosphamide, mesna, fludarabine phosphate, and methylprednisolone. Conditioning and transplant regimen consisted of fludarabine, cyclophosphamide, rituxan, filgrastim, mesna, diphenhydramine and stem cell transplant infusion.


Baseline Measures
    Autologous HSCT in SLE  
Number of Participants  
[units: participants]
  9  
Age  
[units: participants]
 
<=18 years     1  
Between 18 and 65 years     8  
>=65 years     0  
Age  
[units: years]
Mean ± Standard Deviation
  25.85  ± 7.67  
Gender  
[units: participants]
 
Female     7  
Male     2  
Ethnicity (NIH/OMB)  
[units: Participants]
 
Hispanic or Latino     1  
Not Hispanic or Latino     8  
Unknown or Not Reported     0  
Race (NIH/OMB)  
[units: Participants]
 
American Indian or Alaska Native     0  
Asian     2  
Native Hawaiian or Other Pacific Islander     1  
Black or African American     3  
White     3  
More than one race     0  
Unknown or Not Reported     0  
Region of Enrollment  
[units: participants]
 
United States     9  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Relapse-free Complete Clinical Response   [ Time Frame: 60 months ]

2.  Secondary:   Number of Participants With Adverse Events   [ Time Frame: 18 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Steven Pavletic
Organization: National Cancer Institute, National Institutes of Health
phone: 301-402-4899
e-mail: pavletis@mail.nih.gov


Publications:

Responsible Party: Steven Pavletic, M.D., National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier: NCT00076752     History of Changes
Obsolete Identifiers: NCT00726518
Other Study ID Numbers: 040095, 04-C-0095
Study First Received: February 2, 2004
Results First Received: March 25, 2014
Last Updated: June 13, 2014
Health Authority: United States: Federal Government
United States: Food and Drug Administration